Oral Presentation
Abstract Title:
Bulumtatug fuvedotin (BFv; 9MW2821) plus toripalimab in patients with locally advanced or metastatic urothelial carcinoma (la/mUC): Follow-up results from a phase 1b/2 study.
Bulumtatug fuvedotin (BFv; 9MW2821) combined with toripalimab for patients with locally advanced or metastatic urothelial carcinoma (la/mUC): Follow-up results from a phase 1b/2 study
Abstract Number: 4518
Speaker: Professor/Chief Physician/Doctoral Supervisor Sheng Xinan (Department of Genitourinary Oncology, Peking University Cancer Hospital)
Presentation Time:
Local time: June 1, 8:00-9:30
Beijing time: June 1, 21:00-22:30
Poster Presentation
Abstract Title:
Bulumtatug fuvedotin (BFv; 9MW2821) plus toripalimab in perioperative patients with muscle-invasive bladder cancer (MIBC): Results of cohort A from a phase 2 study.
Bulumtatug fuvedotin (BFv; 9MW2821) combined with toripalimab for perioperative patients with muscle-invasive bladder cancer (MIBC): Results from cohort A of a phase 2 study
Abstract Number: 4609
Author: Professor/Chief Physician Liu Zhuowei (Department of Urology, Sun Yat-sen University Cancer Center)
Poster Board Number: 88
Display Time:
Local time: May 31, 9:00-12:00
Beijing time: May 31, 22:00 – June 1, 1:00
About Mabwell
Mabwell (688062.SH) is an innovative biopharmaceutical company with a full industry chain layout. We have always adhered to the vision of “Turning Innovation into Reality” and fulfilled the mission of “Exploring Life, Benefiting Health.” Through original innovation, we provide patients with better efficacy and more accessible innovative biologics to meet unmet global clinical needs. Since its establishment in 2017, Mabwell has built an innovation system covering the entire drug R&D cycle, starting from antibody drug target discovery and molecular discovery, encompassing druggability research, preclinical research, clinical research, and production transformation, achieving a full industry chain layout integrating R&D, production, and marketing. We focus on oncology and age-related diseases, covering therapeutic areas such as oncology, autoimmune diseases, bone diseases, ophthalmology, hematology, and cardiovascular diseases. Leveraging internationally leading distinctive technology platforms and R&D innovation capabilities, we have established a rich and competitive pipeline. Currently, we have 15 key programs in preclinical, clinical, or marketing stages, including 11 innovative programs and 4 biosimilars. Among them, 4 programs have been launched, 1 is under marketing review, and 2 are in Phase III pivotal registration clinical trials. We have independently undertaken 1 national “Major New Drug Creation” major science and technology project, 2 national key R&D plans, and multiple provincial and municipal science and technology innovation projects. Mabwell is innovation-oriented and focuses on industrial transformation. Our antibody and recombinant protein drug industrialization base, compliant with China NMPA, US FDA, and EU EMA GMP standards, has been put into operation in Taizhou, Jiangsu Province, and has passed the EU QP audit. Large-scale commercial production bases in Jinshan, Shanghai, and Taizhou, Jiangsu, are under construction. For more information, please visit: www.mabwell.com.
Forward-Looking Statements
The information released in this press release may contain certain forward-looking statements. These statements are inherently subject to significant risks and uncertainties. When using words such as “anticipate,” “believe,” “predict,” “expect,” “intend,” and other similar expressions, any statements related to the Company are intended to identify them as forward-looking statements. The Company undertakes no obligation to continuously update these forward-looking statements.
These forward-looking statements are based on the Company’s management’s current views, assumptions, expectations, estimates, predictions, and understanding of future events at the time the statements are made. These statements are not guarantees of future developments and are subject to risks, uncertainties, and other factors, some of which are beyond the Company’s control and difficult to predict. Therefore, due to the impact of future changes and developments in our business, competitive environment, and political, economic, legal, and social conditions, actual results may differ materially from the information contained in the forward-looking statements.
The Company, its directors, employees, and agents assume no obligation (a) to correct or update any forward-looking statements contained on this website; and (b) any liability arising from the failure of any forward-looking statement to materialize or becoming inaccurate.